These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 5676035)

  • 21. The influence of the dopa decarboxylase inhibitor Ro4-4602 on the urinary excretion of catecholamines in cold-stressed rats.
    Johnson GE; Pritzker K
    J Pharmacol Exp Ther; 1966 Jun; 152(3):432-8. PubMed ID: 5922312
    [No Abstract]   [Full Text] [Related]  

  • 22. Central hypotensive effect of L-3,4-dihydroxyphenylalanine in the rat.
    Henning M; Rubenson A
    J Pharm Pharmacol; 1970 Aug; 22(8):553-60. PubMed ID: 4394527
    [No Abstract]   [Full Text] [Related]  

  • 23. Dopa decarboxylase in medullary carcinoma of the thyroid.
    Atkins FL; Beaven MA; Keiser HR
    N Engl J Med; 1973 Sep; 289(11):545-8. PubMed ID: 4146664
    [No Abstract]   [Full Text] [Related]  

  • 24. Central hypotensive effect of alpha-methyldopa.
    Henning M; Van Zwieten PA
    J Pharm Pharmacol; 1967 Jun; 19(6):403-5. PubMed ID: 4382373
    [No Abstract]   [Full Text] [Related]  

  • 25. Central hypotensive effect of alpha-methyldopa.
    Henning M; van Zwieten PA
    J Pharm Pharmacol; 1968 Jun; 20(6):409-17. PubMed ID: 4386523
    [No Abstract]   [Full Text] [Related]  

  • 26. POTENT DECARBOXYLASE INHIBITORS. ANALOGS OF METHYLDOPA.
    SLETZINGER M; CHEMERDA JM; BOLLINGER FW
    J Med Chem; 1963 Mar; 6():101-3. PubMed ID: 14188777
    [No Abstract]   [Full Text] [Related]  

  • 27. Central hypotensive effect of alpha-methyldopa.
    Henning M; van Zwieten PA
    Acta Pharmacol Toxicol (Copenh); 1967; 25():Suppl 4:25. PubMed ID: 5630931
    [No Abstract]   [Full Text] [Related]  

  • 28. Site of action of methyldopa in lowering the blood pressure in man.
    Kersting F; Reid JL; Dollery CT
    Clin Exp Pharmacol Physiol Suppl; 1978; 4():11-5. PubMed ID: 277299
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Alphamethyldopa and the catecholamine content of the hypertrophic myocardium].
    Pirrelli R; Pieri R; Dolce E
    Boll Soc Ital Biol Sper; 1978 Feb; 53(24):2424-8. PubMed ID: 147694
    [No Abstract]   [Full Text] [Related]  

  • 30. Alpha-Monofluoromethyldopa (MFMD) in combination with L-DOPA Effects on tissue catecholamines and blood pressure in rats.
    Johansson P; Henning M
    Naunyn Schmiedebergs Arch Pharmacol; 1982 Oct; 321(1):28-31. PubMed ID: 7144925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Further studies on the mechanism of the central hypotensive effect of L-dopa, DL-m-tyrosine and L-alpha-methyldopa.
    Rubenson A
    J Pharm Pharmacol; 1971 Mar; 23(3):228-30. PubMed ID: 4396899
    [No Abstract]   [Full Text] [Related]  

  • 32. A centrally mediated peripheral hypotensive effect of alpha-methyldopa.
    Ingenito AJ; Barrett JP; Procita L
    J Pharmacol Exp Ther; 1970 Dec; 175(3):593-9. PubMed ID: 5489916
    [No Abstract]   [Full Text] [Related]  

  • 33. Histamine in rat brain: sensitive assay of endogenous levels, formation in vivo and lowering by inhibitors of histidine decarboxylase.
    Taylor KM; Snyder SH
    J Pharmacol Exp Ther; 1971 Dec; 179(3):619-33. PubMed ID: 5138032
    [No Abstract]   [Full Text] [Related]  

  • 34. [Endogenous 3-O-methyldopa in man: normal level and effect of an inhibitor of aromatic amino-acid decarboxylase (Benserazid) (author's transl)].
    Geissbühler F; Raffin Y; Combépine C; Streiff U; Hovaguimian T
    J Clin Chem Clin Biochem; 1978 Jun; 16(6):355-8. PubMed ID: 670902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Saligenin analogs of l-DOPA and dl-alpha-methyl-DOPA.
    Atkinson M; Hartley D; Lunts LH; Ritchie AC
    J Med Chem; 1974 Feb; 17(2):248-9. PubMed ID: 4809259
    [No Abstract]   [Full Text] [Related]  

  • 36. Catecholamine accumulation in tissues of thiamine-deficient rats after inhibition of monoamine oxidase.
    Iwata H; Nishikawa T; Baba A
    Eur J Pharmacol; 1970 Oct; 12(2):253-6. PubMed ID: 4394375
    [No Abstract]   [Full Text] [Related]  

  • 37. Antihypertensive agents 1962-1968.
    Schier O; Marxer A
    Prog Drug Res; 1969; 13():101-35. PubMed ID: 4391189
    [No Abstract]   [Full Text] [Related]  

  • 38. Influence of the decarboxylase inhibitor benserazide on the antihypertensive effect and metabolism of alpha-methyldopa in patients with essential hypertension.
    Planz G; Gierlichs HW; Hawlina A; Planz R; Stephany W; Rahn KH
    Eur J Clin Pharmacol; 1977 Dec; 12(4):241-5. PubMed ID: 338308
    [No Abstract]   [Full Text] [Related]  

  • 39. Evidence for a centrally mediated hypotensive effect of L-dopa in the rat.
    Henning M; Rubenson A
    J Pharm Pharmacol; 1970 Mar; 22(3):241-3. PubMed ID: 4399501
    [No Abstract]   [Full Text] [Related]  

  • 40. Blood pressure and noradrenaline levels after treatment with alpha-methyldopa, alpha-methyldopamine and alpha-methyl-m-tyrosine.
    Henning M
    J Pharm Pharmacol; 1967 Nov; 19(11):775-9. PubMed ID: 4383705
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.